The Impact of Drug Changes on Pharma Manufacturing 

As conversations around drug pricing intensify in Washington, manufacturers and packaging leaders alike are watching closely. A recent Packaging Digest article explores how proposed changes to the Inflation Reduction Act – specifically the potential repeal of the “pill penalty” – could signal a shift back toward small-molecule therapies and reshape packaging priorities across the industry. 

In this article, Project Farma CEO Anshul Mangal shares his perspective on what this shift could mean for pharmaceutical operations. From increased demand for high-throughput tablet and capsule production lines to greater reliance on scalable packaging formats like blister packs and bottles, the implications stretch far beyond.  

Read the full article, The Push to Nix the Pill Penalty Could Signal Big Changes for Big Pharma here.